Latest Information Update: 06 Apr 2001
At a glance
- Originator Xcyte Therapies
- Mechanism of Action Immunosuppressants; Lymphocyte inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 06 Apr 2001 Discontinued-Preclinical for Psoriasis in USA (Topical)
- 08 Mar 1999 New profile
- 08 Mar 1999 Preclinical development for Psoriasis in USA (Topical)